Structure via PubChem · Public domain (PubChem)
Abemaciclib
Sign in to saveAlso known as CS-1230, HY-16297A, LY 2835219, LY2835219
chemische Verbindung
Key facts
- Drug.image
- Abemaciclib.svg
- Drug.image_class
- skin-invert-image
- Drug.tradename
- Verzenio, Verzenios, Ramiven, others
- Drug.DailyMedID
- Abemaciclib
- Drug.routes_of_administration
- By mouth
- Drug.ATC_prefix
- L01
- Drug.ATC_suffix
- EF03
- Drug.legal_AU
- S4
- Drug.legal_CA
- Rx-only
- Drug.legal_CA_comment
- / Schedule D
- Drug.legal_US
- Rx-only
- Drug.legal_EU
- Rx-only
- Drug.bioavailability
- 45%
- Drug.protein_bound
- 96.3%
- Drug.elimination_half life
- 18.3 hrs
- Drug.excretion
- 81% via feces, 3% via urine
- Drug.CAS_number
- 1231929-97-7
- Drug.PubChem
- 46220502
via Wikipedia infobox
Chemical data
- Formula
- C27H32F2N8
- Molecular weight
- 506.6 g/mol
- IUPAC name
- N-[5-[(4-ethylpiperazin-1-yl)methyl]-2-pyridinyl]-5-fluoro-4-(7-fluoro-2-methyl-3-propan-2-ylbenzimidazol-5-yl)pyrimidin-2-amine
- SMILES
- CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
- InChIKey
- UZWDCWONPYILKI-UHFFFAOYSA-N
- XLogP
- 3.8
- Polar surface area
- 75 Ų
- H-bond donors
- 1
- H-bond acceptors
- 9
- Formal charge
- 0
via PubChem
Drug data · ChEMBL
- Max clinical phase
- Approved
- Molecule type
- Small molecule
- First approval
- 2017
- Admin. routes
- oral
- Indications
- Mantle cell lymphoma, neoplasm, non-small cell lung carcinoma, breast carcinoma
via ChEMBL · EBI
Wikidata facts
- Subclass of
- chemical compound
- Mass
- 506.272
- Has use
- medication
Show 5 more facts
- Commons category
- Abemaciclib
- chemical formula
- C₂₇H₃₂F₂N₈
- canonical SMILES
- CCN1CCN(CC1)CC2=CN=C(C=C2)NC3=NC=C(C(=N3)C4=CC5=C(C(=C4)F)N=C(N5C(C)C)C)F
- subject has role
- protein kinase inhibitors
- medical condition treated
- breast cancer
via Wikidata · CC0
Article · Deutsch
Abemaciclib ist ein Arzneistoff zur Behandlung bestimmter Formen des Brustkrebses. Er ist ein Vertreter der neuen Wirkstoffklasse der Cyclin-abhängigen Kinase-Inhibitoren und ist oral wirksam. Die Zulassung in den USA erfolgte am 28. September 2017 im Rahmen des beschleunigten Zulassungsverfahrens der FDA (Break Through Therapy), in der Europäischen Union ein Jahr später am 27. September 2018.
Abstract from DBpedia / Wikipedia · CC BY-SA